Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epigenetic Therapeutics to Overcome Resistance Against Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
NCT05873244Phase 2Active, not recruiting
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zabadinostat, geptanolimab in hepatocellular carcinoma (HCC). Started Aug 2023; status: active, not recruiting.
02
Drugs
zabadinostatgeptanolimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05873244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873244.